polydex pharmaceuticals ltd (POLXF) Snapshot

Polydex Pharmaceuticals Ltd. announced earnings results for the first quarter ended April 30, 2013. For the quarter, the company reported sales of $1,440,144 against $1,203,892 a year ago. Net income was $271,916 against net loss of $140,418 a year ago. Diluted income per share was $0.08 against diluted loss per share of 0.04 a year ago. EBITDA improved by $379,007 to $313,779 for the three months ended April 30, 2013 compared to negative EBITDA of $65,228 for the same period in the previous year.

Polydex Pharmaceuticals Ltd. reported earnings results for the fiscal year ended January 31, 2013. For the period, the company’s sales were $5,192,969 against $6,165,754 a year ago. Net loss was $423,549 or $0.13 per basic and diluted share against income of $231,668 or $0.07 per basic and diluted share a year ago. Sales decreased significantly for fiscal year 2013 compared to fiscal year 2012 primarily due to failures in production equipment, which are now being closely monitored. Customer demand remained strong throughout the fiscal year and the order book at year-end and at present is at unprecedented levels.

Polydex Pharmaceuticals Ltd. reported unaudited earnings results for the third quarter and nine months ended October 31, 2012. For the quarter, the company reported sales of $1,385,226 against $1,610,631 a year ago. Net loss was $133,584 or $0.04 per share against net income of $83,231 or $0.03 per share a year ago. For the nine months, the company reported EBITDA (Earnings before interest, taxes, depreciation and amortization) decreased to negative $144,329 compared to $563,823 for the same period in the previous year.